Cite
HARVARD Citation
Struble, K. et al. (2018). Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. Hepatology. 67 (2), pp. 482-491. [Online].